WebJun 20, 2016 · Hypofractionated radiotherapy was not superior to conventional radiotherapy with respect to 5-year relapse-free survival. Our hypofractionated radiotherapy regimen cannot be regarded as the new standard of care for patients with intermediate-risk or high-risk prostate cancer. WebFIRSTANA (ClinicalTrials.gov identifier: NCT01308567) assessed whether cabazitaxel 20 mg/m 2 (C20) or 25 mg/m 2 (C25) is superior to docetaxel 75 mg/m 2 (D75) in terms of …
Cabazitaxel Versus Docetaxel As First-Line Therapy for …
WebFor patients with metastatic castration-resistant prostate cancer (mCRPC), the current standard of care is chemotherapy involving the tubulin-binding taxane docetaxel. However, as the tumor cells become resistant to docetaxel-based therapy, disease progression is inevitable, and until recently there … Web臨床試験 は第I相から第III相の3段階に分けて行われる．第I相試験では，抗がん剤などの場合を除いて，被験薬が健常な成人ボランティアに対して投与され， 薬物動態 や 副作 … parkview hospital randallia address
Fontana Laboratório Clínico - Resultados
WebTRI 医療イノベーション推進センター [公益財団法人 神戸医療産業都市推進機構] WebDec 10, 2012 · n engl j med 368;2 nejm.org january 10, 2013 WebBackground: Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations. Preclinical data suggest synergy between olaparib and androgen pathway inhibitors. We … parkview pediatric developmental clinic